Eric P. Winer

Chief, Division of Women's Cancers at Dana-Farber Cancer Institute, Inc.

Eric P. Winer

Eric P. Winer

Chief, Division of Women's Cancers at Dana-Farber Cancer Institute, Inc.

Overview
RelSci Relationships

3347

Number of Boards

6

Contact Data
Trying to get in touch with Eric P. Winer? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Eric P. Winer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Scientific Officer Chair, Executive Committee for Research (ECR) at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief Scientific Officer & Trustee at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief of Staff Emeritus at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Chief Medical Officer & Medical Director, Adult Ambulatory Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Co-Founder at Tango Therapeutics, Inc.

Relationship likelihood: Strong

Director at Dana-Farber Cancer Institute - Center for Functional Cancer Epigenetics

Relationship likelihood: Strong

Physician at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Pediatric Hematology/Oncology at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Paths to Eric P. Winer
Potential Connections via
Relationship Science
You
Eric P. Winer
Chief, Division of Women's Cancers at Dana-Farber Cancer Institute, Inc.
Education
BA

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

MD

Yale University School of Medicine provides higher education and professional qualifications related to the health industry. It offers the Doctor of Medicine (M.D.) degree and a Master of Medical Science (M.M.Sc.) degree through the Yale Physician Associate Program for prospective physician assistants. Public health degrees are administered through the Yale School of Public Health. It also provides joint degree programs with other disciplines at Yale, including the M.D/Juris Doctor (J.D.) in conjunction with Yale Law School; the M.D./Master of Business Administration (M.B.A.) in conjunction with the Yale School of Management; the M.D./Master of Public Health (M.P.H.) in conjunction with the Yale School of Public Health; science or engineering in conjunction with the Yale Graduate School of Arts and Sciences (M.D./Ph.D.); and the M.D./Master of Divinity (M.Div) in conjunction with Yale Divinity School. Yale University School of Medicine carries out its practical teaching through the Yale-New Haven Hospital. It includes 62 National Academy of Sciences members, 40 Institute of Medicine investigators, and 16 Howard Hughes Medical Institute investigators. It has 718 students and 2,451 academic staff. It was founded in 1810 as The Medical Institution of Yale College, and formally opened its doors in 1813. Yale University School of Medicine is based in New Haven, Connecticut.

Career History
Chair, Drug Discovery & Development Team
2013 - Current

MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients. The MenaCalc, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. The company was founded by Warren C. Lau in July 2009 and is headquartered in Boston, MA.

Chief, Division of Women's Cancers
1997 - Current

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Professor of Medicine
Current

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Boards & Committees
Member, Scientific Advisory Board
Current

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Member, Scientific Advisory Board for Therapeutics
Current

MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients. The MenaCalc, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. The company was founded by Warren C. Lau in July 2009 and is headquartered in Boston, MA.

Member, Board of Directors
Current

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology.American Society of Clinical Oncology is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Chair, Executive Committee for Clinical Programs
Prior - 2015

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$26K - $27K
2017

Pan Mass Challenge is an American private company located in Needham, MA. The firm provides fund raises money for life-saving cancer research and treatment.The company says this about itself: The Pan-Mass Challenge (PMC) is a bike-a-thon that today raises more money for charity than any other single athletic fundraising event in the world. The 41st PMC will take place on August 1 and 2, 2020. The PMC was founded in 1980 by Billy Starr, who remains the event's executive director, an annual cyclist and a fundraiser. The PMC has since raised $717 million for adult and pediatric patient care and cancer research at Dana-Farber Cancer Institute through the Jimmy Fund. The event donates 100 percent of every rider-raised dollar directly to the cause, generating 55 percent of the Jimmy Fund's annual revenue as Dana-Farber's single largest contributor. The PMC has successfully melded support from committed cyclists, volunteers, corporate sponsors and individual contributors, all of which are essential to the PMC's goal and model: to attain maximum fundraising efficiency while increasing its annual gift. The PMC's hope and aspiration is to provide Dana-Farber's doctors and researchers with the necessary resources to discover cures for all cancers.

$15K - $25K
2013

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

$1,000 - $4,999
2012

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology.American Society of Clinical Oncology is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eric P. Winer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eric P. Winer's profile does not indicate a business or promotional relationship of any kind between RelSci and Eric P. Winer.